TrialBreast cancer research and treatment2014
Everolimus plus exemestane as first-line therapy in HR⁺, HER2⁻ advanced breast cancer in BOLERO-2.
J Thaddeus Beck et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
47 papers cite it
this paperpooled ittrialcites it